1. Drug safety update: hydroxychloroquine, chloroquine coadministered with macrolide antibiotics

   News item 12 March 2022 Pages: 1 - 1

2. Health Canada reviews safety of diphenhydramine products in young children

   News item 12 March 2022 Pages: 2 - 2

3. Hypoxia may be sign of dapsone-induced methaemoglobinaemia

   News item 12 March 2022 Pages: 3 - 3

4. Ireland's HPRA updates product information for ibuprofen to include rare skin reaction

   News item 12 March 2022 Pages: 4 - 4

5. Medicines Safety Update and PI changes for administration of vinca alkaloids

   News item 12 March 2022 Pages: 5 - 5

6. TGA warns of risk of donepezil-related QT interval prolongation

   News item 12 March 2022 Pages: 6 - 6

7. Antibacterial use during pregnancy increases risk of preterm birth

   Clinical study 12 March 2022 Pages: 7 - 7

8. Drug safety risk minimisation websites easy to use but with low user engagement

   Clinical study 12 March 2022 Pages: 8 - 8

9. Indapamide-related rhabdomyolysis due to hypokalaemia/hyponatraemia

   Clinical study 12 March 2022 Pages: 9 - 9

10. Myopathy with SGLT-2 inhibitors plus statins versus statins alone

    Clinical study 12 March 2022 Pages: 10 - 10

11. Reviewing case reports of ADRs associated with GLP-1 agonists

    Review 12 March 2022 Pages: 11 - 11

12. Risk of aflibercept- and ranibizumab-related thromboembolic events

    Clinical study 12 March 2022 Pages: 12 - 12

13. Other adverse reaction research

    News item 12 March 2022 Pages: 13 - 13

14. Multiple drugs

    Case report 12 March 2022 Pages: 14 - 14

15. 17DD-yellow-fever-vaccine

    Case report 12 March 2022 Pages: 15 - 15

16. Acetazolamide/fampridine

    Case report 12 March 2022 Pages: 16 - 16

17. Aciclovir

    Case report 12 March 2022 Pages: 17 - 17

18. Ad26.COV2-S

    Case report 12 March 2022 Pages: 18 - 18

19. Ad26.COV2-S/AZD-1222

    Case report 12 March 2022 Pages: 19 - 19

20. Ad26.COV2-S/COVID-19-Vaccine-Pfizer-BioNTec/elasomeran

    Case report 12 March 2022 Pages: 20 - 20

21. Ad26.cov2-s/elasomeran/tozinameran

    Case report 12 March 2022 Pages: 21 - 21

22. Adalimumab/anakinra

    Case report 12 March 2022 Pages: 22 - 22

23. Adalimumab/infliximab

    Case report 12 March 2022 Pages: 23 - 23

24. Alemtuzumab

    Case report 12 March 2022 Pages: 24 - 24

25. Alemtuzumab/cladribine/fingolimod

    Case report 12 March 2022 Pages: 25 - 25

26. Alprazolam/aripiprazole/fluoxetine

    Case report 12 March 2022 Pages: 26 - 26

27. Alteplase

    Case report 12 March 2022 Pages: 27 - 27

28. Ambroxol/ceftazidime

    Case report 12 March 2022 Pages: 28 - 28

29. Aminolevulinic acid

    Case report 12 March 2022 Pages: 29 - 29

30. Amiodarone/aspirin/ibrutinib interaction

    Case report 12 March 2022 Pages: 30 - 30

31. Amiodarone/sunitinib

    Case report 12 March 2022 Pages: 31 - 31

32. Amphotericin B liposomal/posaconazole

    Case report 12 March 2022 Pages: 32 - 32

33. Amphotericin-B

    Case report 12 March 2022 Pages: 33 - 33

34. Amphotericin-B

    Case report 12 March 2022 Pages: 34 - 34

35. Ampicillin/ertapenem/naproxen

    Case report 12 March 2022 Pages: 35 - 35

36. Anaesthetic agents

    Case report 12 March 2022 Pages: 36 - 36

37. Androstenols

    Case report 12 March 2022 Pages: 37 - 37

38. Antiallergics/azacitidine

    Case report 12 March 2022 Pages: 38 - 38

39. Anticoagulants/centaurium erythraea/clarithromycin

    Case report 12 March 2022 Pages: 39 - 39

40. Antiepileptic drugs

    Case report 12 March 2022 Pages: 40 - 40

41. Antifungals/letermovir/tacrolimus

    Case report 12 March 2022 Pages: 41 - 41

42. Antihyperlipidaemics/immunosuppressants

    Case report 12 March 2022 Pages: 42 - 42

43. Antineoplastic/antihypertensive/antidementia drug

    Case report 12 March 2022 Pages: 43 - 43

44. Antineoplastics

    Case report 12 March 2022 Pages: 44 - 44

45. Antineoplastics

    Case report 12 March 2022 Pages: 45 - 45

46. Antineoplastics

    Case report 12 March 2022 Pages: 46 - 46

47. Antineoplastics

    Case report 12 March 2022 Pages: 47 - 47

48. Antineoplastics

    Case report 12 March 2022 Pages: 48 - 48

49. Antineoplastics

    Case report 12 March 2022 Pages: 49 - 49

50. Antineoplastics

    Case report 12 March 2022 Pages: 50 - 50